1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 0 to 30
Sponsor: Other
Protocol IDs: EUDRACT 2005-002618-40, BfArM-4030755, EC-105/05, DKS 2006.01, NCT00749723
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 10 at diagnosis
Sponsor: Other
Protocol IDs: CHLA-HEAD-START-III, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
|
|
3.
|
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 3 to 25
Sponsor: Other
Protocol IDs: SCRT Trial, NCT00517959
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Other
Protocol IDs: CNS 0201, NCT00179907
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 120
Sponsor: Other
Protocol IDs: R01 CA 89395-01, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-110, SUN08-01, NCT00704054
|
|
7.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
8.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: COG-ADVL0912, ADVL0912, NCT00939770
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 20
Sponsor: Other
Protocol IDs: SIOP-EPENDYMOMA-99, AIEOP-EPENDYMOMA-99, CCLG-EPENDYMOMA-99, EU-99001, NCT00004224
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 months to 25 years
Sponsor: Other
Protocol IDs: RT1, NCT00187226
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: CCLG-CNS-2001-4, EU-20576, NCT00278252
|
|
12.
|
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: PBTC-022, NCT00381797
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: NYU 05-40 H12853, PBMTC ONC-032P, NCT00528437
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 3368, NCT00576537
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: CERN08-01, NCT00883688
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 20 years
Sponsor: Other
Protocol IDs: CSET 2008/1378, NCT00918320
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 1 to 21
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: OSI-774-205, NCT01032070
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-02-C-0031, 02-C-0031, 5425, NCI-5425, NCT00030108
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI
Protocol IDs: UIHC-200008086, NCI-V02-1710, NCT00049023, 200008086
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 months and over
Sponsor: NCI
Protocol IDs: OHSU-1299, OHSU-ONC-98018-L, OHSU-4834, NCT00253721
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: PBTC-020, NCT00326664
|
